database > company
GenVec
Biotech Specialty Pharma
65 West Watkins Mill Road
Gaithersburg, MD 20878 USA
phone:(240) 632-0740
fax:(240) 632-0735
Symbol GNVC
Exchange NASDAQ
Founded 0
Employees 88
     www.genvec.com
Research Sector Biotech Specialty Pharma
Summary Description
Therapeutic drugs and vaccines
Management
Paul H. Fischer, Ph.D., President and Chief Executive Officer and Director; Douglas J. Swirsky, Senior Vice President, Chief Financial Officer, Treasurer and Corporate Secretary; Bryan T. Butman, Ph.D., Senior Vice President of Vector Operations; Milan Kovacevic, M.D., Ph.D., Vice President of Clinical Operations; Mark O. Thornton, M.D., M.P.H., Ph.D., Senior Vice President of Product Development
Ownership
Financials Mkt Cap :182
* numbers in thousands
 
Keywords
radiotherapy, fluorouracil, hydorxyurea, pancreatic cancer, gemcitabine


Comment | Printable Version | Modify profile Jan. 06, 2010

Description
GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. Each of their product candidates uses patent-protected technology to deliver genes that produce beneficial proteins. GenVec’s lead product, TNFerade, is currently in a pivotal, Phase III clinical study (PACT) in locally advanced pancreatic cancer. TNFerade has also been and is currently being evaluated for its potential use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2.
Technology / Differentiation
Modification of the Ad35 Fiber to Ablate CD46 Binding, Adenovirus Complementing Cell Line for the Construction of Vectors with Inhibitory Transgenes, Adenovirus 35 Vectors with Improved Transgene Capacity, and Ease of Production
Status
Its most advanced product candidates are: TNFerade, which is in Phase II trials for the treatment of locally advanced pancreatic cancer and for the treatment of non-metastatic esophageal cancer; BIOBYPASS, which has completed a Phase II trial in 71 patients with severe heart disease who have no treatment options, and AdPEDF, which is in a Phase I trial for the treatment of wet age-related macular degeneration, a leading cause of blindness in individuals over the age of 50.


2010-02-09-232